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Aims More treatments are needed to improve clinical outcomes in chronic heart failure (HF). It is,
however, important that treatments for a condition as common as HF are affordable. We have
carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity (CHARM) programme.
Methods and results Patients with NYHA class II–IV HF and LVEF 0.40 were randomized to
CHARM-Alternative if intolerant of an ACE-inhibitor or to CHARM-Added if taking an ACE-inhibitor.
Patients with a LVEF .0.40 were randomized in CHARM-Preserved. Each trial compared the effect of
candesartan to placebo on the primary outcome of cardiovascular death or HF hospitalization. Detailed
information was prospectively collected on hospital admissions, procedures/operations and drugs. A
cost–consequence analysis was performed for France, Germany and the UK for CHARM-Overall and a cost-
effectiveness analysis for the low LVEF trials. The cost of candesartan was substantially offset by a
reduction in hospital admissions, especially for HF. In the cost–consequence analysis, candesartan was
cost-saving in most scenarios for CHARM-Alternative and Added but the marginal annual net cost per
patient was upto E372 per year in CHARM-Preserved, in which candesartan did not reduce the primary
outcome signiﬁcantly. In the cost-effectiveness analysis of patients with a LVEF  0.40, candesartan
was cost-saving in some scenarios and in the others the maximum cost per life year gained was E3881.
Conclusion Candesartan improves functional class, reduces the risk of hospital admission, and







Despite the availability of several effective treatments,1,2
patients with chronic heart failure (HF) continue to experi-
ence marked functional limitation because of symptoms,
reduction in quality of life, frequent admission to hospital,
and greatly shortened life-expectancy.3–7 Consequently, HF
continues to be a major public health problem, for which
new treatments are needed.8 For a condition as prevalent
as HF, the cost of any new treatment (and whether it is justi-
ﬁed) is, inevitably questioned.9–14 We have recently shown
that the angiotensin II type 1 receptor blocker (ARB)
candesartan reduces symptomatic limitation and decreases
the risk of hospital admission for worsening HF and deaths
due to cardiovascular causes, when added to conventional
treatment in a broad spectrum of patients with symptomatic
HF randomized in the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM)
programme.15–21 An economic evaluation of this programme
was pre-speciﬁed and data on resource use were collected
prospectively. Here we describe within-trial cost–
consequence and cost-effectiveness analyses of CHARM.15
Methods
The CHARM programme
The design, baseline ﬁndings, and primary results of the CHARM pro-
gramme have been reported in detail.15–21 Brieﬂy, the CHARM
programme consisted of three independent but related trials in
which patients with NYHA class II–IV HF were randomized to
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placebo or candesartan (target dose 32 mg once daily). In
CHARM-Added, patients in NYHA Class II had to have had a hospital
admission for a cardiac reason in the previous 6 months (this had the
effect of increasing the proportion of NYHA class III/IV patients in
CHARM-Added). Patients were enrolled into the individual CHARM
trials according to left ventricular (LV) ejection fraction (EF)
(LVEF) and baseline treatment with an ACE-inhibitor. Patients with
an LVEF 0.40 and intolerant of an ACE-inhibitor, were enrolled in
CHARM-Alternative,17 whereas patients with an LVEF 0.40 and
taking an ACE-inhibitor were enrolled in CHARM-Added.18 Patients
with an LVEF .0.40 were randomized into CHARM-Preserved.19
The CHARM programme was completed, as planned, 2 years after
the last patient was randomized. Because the rate of recruitment
varied between the CHARM trials, overall follow-up ranged from a
median of 41 [interquartile (IQR) range 35–44] months in
CHARM-Added, to 37 (34–41) months in CHARM-Preserved, 34
(27–41) months in CHARM-Alternative, and 38 (32–42) months in
the overall CHARM programme.17–20
Economic analysis of CHARM
These analyses were based on the comparison of placebo, i.e. con-
ventional treatment for HF (combination of a diuretic, digoxin,
ACE-inhibitor, beta-blocker, and spironolactone, as indicated and
tolerated) to candesartan added to conventional treatment. We
examined the effect of adding candesartan in all 7599 patients ran-
domized in 26 countries. For the purposes of the economic analysis,
however, all patients were considered to have been managed in
France, Germany, or the UK. Our analysis takes the perspective of
a third party payer in France and Germany and the National
Health Service (NHS) in the UK. Information was collected prospec-
tively on drug treatment, patients admitted to hospital (proportion
admitted, number of admissions per patient, number of hospital
days per patient), admissions for cardiovascular reasons (number,
duration, ward type), and procedures/operations as described
below. These data were used to determine the additional direct
costs incurred, and potential savings made with candesartan.
Indirect costs such as loss of productivity and earnings due to inability
to work were not considered. The analysis period was that of the trial
concerned and the programme overall; no future projections were
made.
Effectiveness measures
As described in detail elsewhere, the primary clinical outcome in
the component trials of the CHARM programme was the composite
of cardiovascular death or hospital admission for worsening
HF.15–21 The candesartan to placebo hazard ratio for this outcome
in CHARM-Alternative was 0.77 (95% CI 0.67–0.89, P ¼ 0.0004),17
in CHARM-Added 0.85 (0.75–0.96, P ¼ 0.011),18 in CHARM-Preserved
0.89 (0.77–1.03, P ¼ 0.118),19 and in the overall CHARM programme
0.84 (0.77–0.91, P, 0.0001).20
All-cause mortality was the pre-speciﬁed primary endpoint of the
overall CHARM programme and of the two reduced LVEF trials com-
bined (CHARM-Alternative and Added).15 The candesartan to
placebo hazard ratio for this outcome in the overall CHARM pro-
gramme was 0.91 (0.83–1.00,20 P ¼ 0.055) and in the reduced
LVEF trials 0.88 (0.79–0.98, P ¼ 0.018).21
Resource use
Hospital admissions. For cardiovascular admissions, investigators
were asked to specify the type of ward (intensive/coronary care
unit, cardiology, general internal medicine) patients were admitted
to and the number of days spent in each type of ward.
For non-cardiovascular admissions only, length of stay (and not
ward type) was collected. For these admissions, we assumed that
10% of time was spent in intensive care and 90% on an internal medi-
cine ward.
Procedures. Investigators were asked to provide information on car-
diovascular procedures and operations (a checklist menu was pro-
vided). Non-cardiovascular procedures were not recorded and
were assumed to be equal in the two groups.
Drug treatment. Investigators classiﬁed medication as
cardiovascular or non-cardiovascular. We assumed that non-
cardiovascular medication did not differ between treatment
groups (and was not, therefore, used in this analysis).
‘Cardiovascular’ medication included digitalis glycosides, diuretics,
beta-blockers, calcium channel blockers, other vasodilators, anti-
arrhythmic drugs, ACE-inhibitors, ARBs, and other cardiovascular
drugs such as lipid-lowering agents and anticoagulants.
Estimation of costs
Hospital admissions
Two approaches were used, as described previously (Table 1).22
. Diagnosis-related group (DRG) costs were obtained from govern-
ment sources in France, Germany, and the UK.23–28
. Per diem (hospital bed-day) costs were also obtained from ofﬁcial
sources in these countries.23–28 In this analysis actual recorded
days in hospital were multiplied by the daily unit costs of hospital
care.
Drug treatment
Drug costs were obtained from standard tariffs for the ﬁnancial year
2003–04 (Vidal, France; Rote Liste, Germany; British National
Formulary, UK).29–32 Daily dose was multiplied by the cost per
dose to calculate the daily cost of treatment. Where available,
the costs of generic drugs were used. Dispensing fees were included
in the public price of candesartan. We added costs to account for
the initiation and up-titration of candesartan, namely four extra
GP visits and four checks of blood biochemistry, as previously
described.22
Cardiovascular procedures
The DRG costs of cardiovascular procedures and operations were
obtained from local government sources.23–29 Because little reliable
and comparable public information is available for the per diem
costs of cardiovascular procedures, DRG costs were used as proxies
in the per diem analysis.
All costs were converted to 2003 values using the local price index
with the exception of drug prices which are for 2003–04. Costs are
presented in the local currency (£ and E) where £1 ¼ 1.79 US$ and
1E ¼ 1.20 US$. The recommended discount rate of 3% was used.33
The costs used in this analysis are summarized in Table 1.
Economic analyses performed
Two types of economic analysis were performed:
. A cost–consequence analysis was performed for each component
trial and for the overall CHARM programme. In this, we used the
primary outcome of the component trials as the measure of effec-
tiveness i.e. we calculated the cost per patient treated to post-
pone or prevent one patient experiencing a cardiovascular
death or hospital admission for worsening HF within the trial.34
. Incremental cost-effectiveness ratios [cost per life year gained
(LYG)] were calculated for the reduced LVEF trials as, in these
two trials combined, there was a signiﬁcant increase in survival
with candesartan. This analysis was not performed for CHARM-
Preserved as there was no reduction in cardiovascular or all
cause mortality in that trial with candesartan.
Sensitivity analyses
The following sensitivity analyses were conducted: (i) we increased
the length of non-cardiovascular hospital stay by 30% to model for
the potential additional cost of certain adverse effects (e.g. renal
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impairment) in the candesartan group;35 (ii) we added costs related
to adverse effects not leading to hospital admission e.g. hypoten-
sion, renal impairment (those leading to admission are accounted
for in base-case scenario), namely one extra general practice visit
for each patient requiring dose reduction or treatment discontinu-
ation for an adverse effect or laboratory abnormality; (iii) we
varied the length of hospital stay in the per diem analysis by
+20% and (iv) for the UK only, we discounted costs by 3.5%, as rec-
ommended by the National Institute for Clinical Excellence (NICE).
Statistical methods
Statistical analysis was performed using SAS software (version 8; SAS
Institute Inc., Cary, NC, USA). The group mean approach was used to
account for early dropouts and missing values, as recommended by
Cook et al.36 Bootstrapping was used to test for signiﬁcance.
Role of the funding source
The CHARM programme was funded by AstraZeneca PLC, who
managed the data and whose representatives were involved in the
data analysis. The economic analysis was planned by all authors
and supervised by J.Mc.M. All data were independently checked
by S.S. and J.Mc.M. All authors were involved in interpretation of
the data and writing of the manuscript which was prepared indepen-
dently of the sponsor.
Results
Candesartan was taken by 50.0% of randomized patients
(n ¼ 3803) for 1050 (SD 318) days on average; the comparable
ﬁgures for placebo (n ¼ 3796) were 50.0% and 1029 (SD 345)
days. The mean daily doses of candesartan taken were
16.8 mg in CHARM-Alternative, 16.9 mg in CHARM-Added,
and 19.0 mg in CHARM-Preserved (17.7 mg overall), based
on all patients in the study over the whole study period.
Clinical effects of candesartan
Hospital admissions—all causes
The rates and number of hospital admissions in the overall
CHARM programme and each component trial are shown in
Table 1 Unit costs used in the economic analysis of CHARM
Event DRG costs
France 2003 Germany 2003 UK 2003
Hospitalizations
Worsening HF 4 174 2 951 2 173
Myocardial infarction 4 579 4 140 2 045
Unstable angina 2 526 1 944 1 150
Stroke
Haemorrhagic 4 394 3 855 2 588
Ischaemic/Unknown/Other 4 394 3 855 3 408
Transient ischaemic attack 2 520 2 445 1 444
Cardiogenic shock 2 779 2 398 1 711
Atrial tachyarrhythmia 2 675 1 876 1 411
Ventricular arrhythmia 2 804 4 615 1 411
Pulmonary embolism 4 969 3 929 2 115
Other cardiovascular event 3 257 1 770 1 368
Cancer (neoplasm) 4 826 3 288 1 960
Other non-cardiovascular event 4 560 2 525 1 235
Cardiovascular procedures
Cardiac catheterizations including angiography 3 199 1 517 1 668
Coronary artery bypass grafting (CABG) 15 289 11 363 9 491
Percutaneous transluminal coronary
intervention (PTCA) with stent
6 166 3 209 5 818
PTCA without stent 2 981 2 736 3 729
Implantation of cardioverter deﬁbrillator 8 557 23 299 22 955
Implantation of pacemaker 8 581 6 575 5 237
Heart transplantation 73 983 44 864 24 929
Ventricular assist device 7 294 6 903 59 667
Other cardiac surgery for HF 18 303 13 906 9 086
Other cardiovascular procedure/operation 7 426 6 221 3 670
Per diem costs
Intensive/coronary care unit 1 611 871 1 864
Cardiology ward 682 265 634
General medical ward 520 240 413
Non-cardiovascular admission 629 303 558
Visit general practitioner (GP) 18.60 39.20 29.08
Laboratory test—blood biochemistry 9 1.79 34.3
Candesartan 4 mg 0.62 0.76 0.48
Candesartan 8 mg 0.81 0.88 0.57
Candesartan 16 mg 0.88 1.04 0.73
Candesartan 32 mg 1.15 1.24 0.92
All costs shown in Euro (1E ¼ $1.20 and £0.67).
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Table 2 and Figures 1 and 2. Overall, 63.8% of patients in the
placebo (conventional treatment) group were admitted to
hospital at least once for any reason. This when compared
with 62.4% in the candesartan group [odds ratio (OR) 0.94,
95% CI 0.86–1.03, P ¼ 0.20]. The number of admissions per
patient hospitalized was 2.96 in the placebo group when
compared with 2.82 in the candesartan group (P ¼ 0.045).
The average length of an individual admission was 8.9 days
in the placebo group and 9.0 days in the candesartan
group. The average number of days spent in hospital for
admitted patients was 26.3 days in the placebo group and
25.2 days in the candesartan group. As a result, treatment
with candesartan resulted in fewer hospital admissions
(placebo 7182, candesartan 6691 or 1.060 compared with
0.853 admissions per year of follow-up, P ¼ 0.0001) and
fewer days in hospital (placebo 63 681, candesartan
59 923; Table 2, P ¼ ns). The number of days in hospital
per patient-year of follow-up was 6.0 in the placebo group
and 5.5 in the candesartan group (P ¼ 0.056).
Hospital admissions—speciﬁc causes
Table 3 and Figure 2 show the breakdown of patients
admitted (and hospital admissions) by speciﬁc causes.
candesartan reduced both the proportion of patients
admitted (220%) and the number of admissions (228%) for
worsening HF. There was also a trend towards a reduction
in atrial tachyarrhythmias. Conversely, there was signiﬁcant
increase in hospitalizations for hypotension (though the
absolute numbers for this adverse effect were small i.e. 49
patients in the placebo group and 98 in the candesartan
group). These ﬁndings were consistent across the com-
ponent trials except for ‘other’ cardiovascular admissions,
which were fewer in the candesartan group in CHARM-
Alternative and CHARM-Added, but numerically greater in
the candesartan group in CHARM-Preserved. Examination
of these miscellaneous admissions did not reveal an excess
in any speciﬁc category of event.
Procedures and operations
Cardiovascular procedures are shown in Table 4. The number
of procedures, other than cardiac catheterization, was small
and did not differ between treatment groups.
Cost of adjunctive candesartan treatment:
per diem analysis
The costs of adding candesartan to conventional treatment
(compared with placebo added to conventional treatment),
based on the analysis using the per diem costs, are shown in
Table 5.
For France and the UK, the cost of care in the candesartan
group was slightly (1–2%) less, even taking into account the
cost of candesartan. For Germany, the overall cost of care
was slightly higher (4%) in the candesartan group.
The costs of adding candesartan to conventional treatment
differed by component trial in the CHARM programme. For all
countries, there was a net cost-saving in CHARM-Alternative
(0.3–7% reduction in cost) and either no additional cost or a
cost-saving in CHARM-Added (0–7% reduction). In CHARM-
Preserved, there was a net increase in the daily cost of care
for all countries (6–12% increase in cost).
Cost of adjunctive candesartan treatment:
DRG analysis
Table 6 shows the results of this analysis in the same way as
Table 5 did for the per diem analysis. Although the costs of
procedures were higher in France and Germany (and
bed-day costs lower) than in the UK, the results of the DRG
analysis were very similar to those of the per diem analysis.
There was a small increase (2–6%) in the net daily cost of
care with candesartan for all three countries using the DRG
approach. Again, for all the three countries, the estimated
net costs with candesartan were generally less in the CHARM-
Alternative and -Added trials than in CHARM-Preserved.
Cost–consequence analyses
Translating the clinical ﬁndings and the daily costs into
annual estimates gives the cost–consequence analysis
shown in Table 7. Adjunctive treatment with candesartan
in CHARM-Alternative and CHARM-Added led to clinical
beneﬁts and to either cost-savings or a small additional
annual cost, depending on trial and country. The less
certain clinical beneﬁt in CHARM-Preserved was obtained
at a modest extra annual cost in all the three countries.
Cost-effectiveness analyses
Table 8 summarizes the cost-effectiveness analyses of the
two reduced LVEF CHARM trials. These results were calcu-
lated using only DRG costs as all scenarios with per diem
costs were cost-saving in all countries. Using French DRG
costs, candesartan was cost-saving in the reduced LVEF trials
individually and combined. In Germany, the cost per LYG
incremental cost-effectiveness ratio (ICER) was estimated to
range from E1427 (CHARM-Added) to E3881(CHARM-
Alternative). The results for the UK lay between those of
France and Germany, i.e. candesartan was cost-saving in
CHARM-Added and the ICER was greatest (but still relatively
small) in CHARM-Alternative at E2547 per LYG.
Sensitivity analyses
Increasing the length of stay for non-cardiovascular admis-
sions by 30% increased the cost per day in the candesartan
group by 15–20%. As a result, candesartan was no longer
cost-saving in any comparison.
Adding one GP visit for an adverse event or laboratory
abnormality which led to a reduction in the dose of, or dis-
continuation of, candesartan resulted in an increase in daily
costs of E0.01–0.02.
Varying the length of hospital stay for all admissions by
+20% varied costs in both groups accordingly, but did not
change the general conclusions.
Using a 3.5% discount rate did not change the UK results
much. Total daily costs were reduced by about E0.04–0.11
in each of the CHARM trials individually and overall, with
a similar change in both treatment groups.
Discussion
It is widely accepted that HF accounts for 2% of direct
health care costs in more developed countries and up to
70% of these are expended on hospital admissions.9–14
Furthermore, the public health (and economic) burden of
HF is widely perceived to be increasing because of the
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Table 2 Hospital admissions (any cause) and patients hospitalized (for any cause) in CHARM (totals and means)
Placebo (n ¼ 1015) Candesartan (n ¼ 1013) Diff (95% CI) P-value
CHARM-Alternative
All patients
Patient-years 2 582 2 658
No. of deaths 296 265
No. admissions 1 835 1 719
No. hospital days 16 816 15 079
Hospital days/admission 9.16 8.77 0.39 (20.60, 1.38) 0.44
Admissions/patient 1.81 1.70 0.11 (20.10, 0.32) 0.30
Hospital days/patient 16.57 14.89 1.86 (21.11, 4.47) 0.24
Hospital days/patient-year 6.51 5.67 0.84 (20.27, 1.95) 0.13
Patients hospitalized
No. hospitalized patients 643 610 0.88 (0.73, 1.05) 0.15
Admissions/patient 2.85 2.82 0.04 (20.25, 0.32) 0.80
Hospital days/patient 26.15 24.72 1.43 (22.73, 5.60) 0.50
Placebo (n ¼ 1272) Candesartan (n ¼ 1276) Diff (95% CI) P-value
CHARM-Added
All patients
Patient-years 3 721 3 846
No. of deaths 412 377
No. admissions 2 799 2 462
No. hospital days 24 161 21 902
Hospital days/admission 8.63 8.90 20.26 (20.95, 0.43) 0.45
Admissions/patient 2.20 1.93 0.27 (0.07, 0.47) 0.008
Hospital days/patient 18.99 17.16 1.83 (20.65, 4.31) 0.15
Hospital days/patient-year 6.49 5.70 0.79 (20.06, 1.64) 0.070
Patients hospitalized
No. hospitalized patients 858 852 0.97 (0.82,1.14) 0.71
Admissions/patient 3.26 2.89 0.37 (0.13, 0.62) 0.003
Hospital days/patient 28.16 25.71 2.45 (20.94, 5.85) 0.16
Placebo (n ¼ 1509) Candesartan (n ¼ 1514) Diff (95% CI) P-value
CHARM-Preserved
All patients
Patient-years 4 387 4 434
No. of deaths 244 237
No. admissions 2 548 2 510
No. hospital days 22 705 22 942
Hospital days/admission 8.91 9.14 20.23 (21.02, 0.56) 0.57
Admissions/patient 1.69 1.66 0.03 (20.13, 0.20) 0.71
Hospital days/patient 15.05 15.15 20.11 (22.20, 2.01) 0.92
Hospital days/patient-year 5.18 5.17 0.01 (20.73, 0.75) 0.98
Hospitalized patients
No. hospitalized patients. 922 912 0.96 (0.83, 1.12) 0.63
Admissions/patient 2.76 2.75 0.01 (20.21, 0.23) 0.92
Hospital days/patient 24.63 25.16 20.53 (23.71, 2.65) 0.74
Placebo (n ¼ 3796) Candesartan (n ¼ 3803) Diff (95% CI) P-value
CHARM-Overall
All patients
Patient-years 10 690 10 938
No. of deaths 945 886
No. admissions 7 182 6 691
No. hospital days 63 681 59 923
Hospital days/admission 8.87 8.96 20.09 (20.55, 0.38) 0.71
Admissions/patient 1.89 1.76 0.13 (0.02, 0.24) 0.018
Hospital days/patient 16.78 15.76 1.02 (20.38, 2.42) 0.15
Hospital days/patient-year 5.96 5.48 0.48 (20.02, 0.98) 0.056
Hospitalized patients
No. hospitalized patients 2 423 2 374 0.94 (0.86, 1.03) 0.20
Admissions/patient 2.96 2.82 0.15 (0.003, 0.29) 0.045
Hospital days/patient 26.28 25.24 1.04 (20.99, 3.07) 0.31
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Figure 1 Cumulative number of hospital admissions: CHARM-Alternative (top left), CHARM-Added (top right), CHARM-Preserved (bottom left), CHARM-Overall
(bottom right).
Figure 2 Rates of hospital admission for any cause, all cardiovascular reasons, HF only, and non-cardiovascular reasons. The numbers in parentheses refer to the
P-values for the comparison of the candesartan and placebo groups.
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Table 3 Hospital admissions by cause—number of admissions and number and proportion of patients admitted
Alternative Added Preserved Overall

















Worsening HF 608 291 (28.7) 445 212 (20.9)† 836 382 (30.0) 607 323 (25.3)** 566 279 (18.5) 402 230 (15.2)* 2010 952 (25.1) 1454 765 (20.1)†
Myocardial
infarction
51 45 (4.4) 55 48 (4.7) 64 50 (3.9) 38 36 (2.8) 64 61 (4.0) 68 58 (3.8) 179 156 (4.1) 161 142 (3.7)
Unstable angina 109 74 (7.3) 137 94 (9.3) 192 117 (9.2) 145 101 (7.9) 235 145 (9.6) 244 154 (10.2) 536 336 (8.8) 526 349 (9.2)
Stroke 34 32 (3.2) 35 32 (3.2) 38 34 (2.7) 37 34 (2.7) 56 52 (3.4) 52 46 (3.0) 128 118 (3.1) 124 112 (3.0)
TIA 16 15 (1.5) 16 12 (1.2) 10 9 (0.7) 20 19 (1.5) 25 21 (1.4) 21 18 (1.2) 51 45 (1.2) 57 49 (1.3)
Hypotension 14 14 (1.4) 26 20 (2.0) 24 22 (1.7) 60 55 (4.3)† 15 13 (0.9) 25 23 (1.5) 53 49 (1.3) 111 98 (2.6)†
Atrial
tachyarrhythmia
44 34 (3.4) 53 34 (3.4) 56 46 (3.6) 61 49 (3.8) 123 86 (5.7) 82 59 (3.9)* 223 166 (4.4) 196 142 (3.7)
Ventricular
arrhythmia
55 39 (3.8) 52 45 (4.4) 86 65 (5.1) 68 52 (4.1) 16 14 (0.9) 18 17 (1.1) 157 118 (3.1) 138 114 (3.0)
Pulmonary
embolism
9 8 (0.8) 6 6 (0.6) 11 10 (0.8) 6 6 (0.5) 9 9 (0.6) 8 8 (0.5) 29 27 (0.7) 20 20 (0.5)
Other CV event 244 181 (17.8) 225 164 (16.2) 416 254 (20.0) 362 249 (19.5) 368 247 (16.4) 400 280 (18.5) 1028 682 (18.0) 987 693 (18.2)
CV unknown 1 1 (0.0) 1 1 (0.0) 1 1 (0.0) 1 1 (0.0)
Cancer 55 35 (3.4) 42 30 (3.0) 49 36 (2.8) 83 52 (4.1) 84 52 (3.4) 53 40 (2.6) 188 123 (3.2) 178 122 (3.2)
Other non-CV
event
596 334 (32.9) 627 350 (34.6) 1017 531 (41.8) 975 525 (41.1) 986 546 (36.2) 1136 589 (38.9) 2599 1411 (37.2) 2738 1464 (38.5)
All 1835 643 (63.4) 1719 610 (60.2) 2799 858 (67.5) 2462 852 (66.8) 2548 922 (61.1) 2510 912 (60.2) 7182 2423 (63.8) 6691 2374 (62.4)
TIA, transient ischaemic attack; CV, cardiovascular.
*P , 0.05.
**P , 0.01.

















Table 4 Number of cardiovascular procedures in CHARM
Procedure Alternative Added Preserved Overall
Placebo
(n ¼ 1 015)
Candesartan
(n ¼ 1 013)
Placebo
(n ¼ 1 272)
Candesartan
(n ¼ 1 276)
Placebo
(n ¼ 1 509)
Candesartan
(n ¼ 1 514)
Placebo
(n ¼ 3 796)
Candesartan
(n ¼ 3 803)
Cardiac catheterization
including angiography
160 139 228 172 261 262 649 573
CABG 26 21 22 39 42 46 90 106
PTCA with stent 31 30 55 36 73 78 159 144
PTCA without stent 11 10 19 10 23 15 53 35
Implantation of cardioverter
deﬁbrillator
31 30 60 51 9 9 100 90
Implantation of pacemaker 50 49 75 80 54 67 179 196
Heart transplantation 8 7 15 17 0 0 23 24
Ventricular assist device 6 6 3 1 0 1 9 8
Other cardiac surgery for HF 3 2 6 9 10 11 19 22
Other cardiovascular
procedure/operation
112 112 213 188 196 192 521 492
Total no. of CV procedures 438 406 696 603 668 681 1802 1690
Total no. of patients with
CV procedure
(percent of patients)
239 (23.6) 218 (21.5)
(P ¼ 0.27)
349 (27.4) 320 (25.1)
(P ¼ 0.18)
350 (23.2) 342 (22.6)
(P ¼ 0.69)
938 (24.7) 880 (23.1)
(P ¼ 0.11)








Table 5 Daily per patient cost of treatment in CHARM—per diem analysis (standard errors within brackets)
Cost item Alternative Added Preserved Overall
Placebo Candesartan Placebo Candesartan Placebo Candesartan Placebo Candesartan
France (E)
Hospitalizations 13.26 11.60 13.06 11.44 10.42 10.37 12.03 11.05
Cardiovascular
procedures
3.44 3.09 3.87 3.69 2.55 2.61 3.22 3.11
Concomitant
medication
1.62 1.56 1.99 1.94 1.60 1.53 1.74 1.68
Study drug 0 0.91 0 0.89 0 0.93 0 0.91
Total 18.33 (3.47) 17.16 (2.23) 18.91 (1.36) 17.96 (1.40) 14.56 (1.40) 15.44 (1.02) 16.98 (1.18) 16.74 (0.86)
Germany (E)
Hospitalizations 6.37 5.57 6.28 5.51 5.01 5.00 5.78 5.32
Cardiovascular
procedures
2.94 2.68 3.42 3.19 1.89 1.93 2.67 2.55
Concomitant
medication
1.76 1.73 1.91 1.89 1.71 1.63 1.79 1.74
Study drug 0 1.05 0 1.02 0 1.07 0 1.05
Total 11.06 (1.80) 11.03 (1.15) 11.61 (0.82) 11.61 (0.77) 8.61 (0.76) 9.63 (0.59) 10.25 (0.63) 10.67 (0.47)
UK (£)
Hospitalizations 12.71 11.10 12.47 10.94 9.95 9.89 11.50 10.55
Cardiovascular
procedures
2.79 2.56 2.94 2.58 1.61 1.68 2.36 2.21
Concomitant
medication
1.45 1.42 1.61 1.59 1.43 1.36 1.49 1.46
Study drug 0 0.81 0 0.78 0 0.81 0 0.79
Total 16.95 (2.68) 15.89 (1.48) 17.02 (0.82) 15.89 (0.81) 12.99 (0.84) 13.74 (0.71) 15.35 (0.84) 15.02 (0.56)
Cardiovascular procedures are based on DRG rates.
Table 6 Daily per patient cost of treatment in CHARM—DRG analysis (standard errors within brackets)
Cost item Alternative Added Preserved Overall
Placebo Candesartan Placebo Candesartan Placebo Candesartan Placebo Candesartan
France (E)
Hospitalizations 6.33 5.70 6.55 5.55 4.95 4.84 5.84 5.30
Cardiovascular procedures 3.44 3.09 3.87 3.69 2.55 2.61 3.22 3.11
Concomitant medication 1.62 1.56 1.99 1.94 1.60 1.53 1.74 1.68
Study drug 0 0.91 0 0.89 0 0.93 0 0.91
Total 11.39 (1.07) 11.26 (1.76) 12.40 (0.88) 12.07 (0.78) 9.09 (0.68) 9.91 (0.56) 10.80 (0.62) 11.00 (0.45)
Germany (E)
Hospitalizations 4.14 3.70 4.20 3.50 3.06 2.92 3.72 3.32
Cardiovascular procedures 2.94 2.68 3.42 3.19 1.89 1.93 2.67 2.55
Concomitant medication 1.76 1.73 1.91 1.89 1.71 1.63 1.79 1.74
Study drug 0 1.05 0 1.02 0 1.07 0 1.05
Total 8.84 (1.41) 9.16 (0.81) 9.53 (0.69) 9.61 (0.55) 6.66 (0.46) 7.55 (0.45) 8.18 (0.48) 8.67 (0.34)
UK (£)
Hospitalizations 2.57 2.22 2.55 2.11 1.86 1.73 2.27 1.98
Cardiovascular procedures 2.79 2.56 2.94 2.58 1.61 1.68 2.36 2.21
Concomitant medication 1.45 1.42 1.61 1.59 1.43 1.36 1.49 1.46
Study drug 0 0.81 0 0.78 0 0.81 0 0.79
Total 6.80 (1.53) 7.01 (0.49) 7.09 (0.36) 7.06 (0.25) 4.91 (0.28) 5.58 (0.38) 6.13 (0.44) 6.44 (0.22)
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ageing of populations in developed countries (elderly indi-
viduals having a greater prevalence of cardiovascular
disease) and improving survival from conditions increasing
the risk of future HF (e.g. myocardial infarction).8,11
Consequently, it is hoped that new treatments for HF will
not only improve symptoms and reduce mortality, but also
decrease hospital admissions and, in doing so, cut costs.
Given the relationship between the cost of hospitalization
and the overall cost of HF to society, any treatment that
substantially reduces hospital admission rates is likely to
be cost-effective.10,14 That is precisely what we found in
this pre-planned economic analysis of CHARM. A substantial
reduction in the proportion of patients admitted with wor-
sening HF (and an even more marked reduction in the
number of such admissions), without any increase in
length of stay, contributed to a reduction in the rate of
admission (and hospital bed days) for any reason, though
this overall reduction was more modest. This is because
the full impact of the reduction in admissions for worsening
HF was attenuated by increased survival in the
candesartan-treated patients (who, therefore, spent more
time at risk of hospital admission for other reasons).
Nevertheless, the cost-savings accruing from even this
modest reduction in the rate of hospital admission for any
cause largely offset the cost of candesartan. Though the
ﬁnal result varied slightly between the countries studied
and according to the method of analysis (per diem compared
with DRG), candesartan was, essentially, cost-neutral in the
overall-CHARM programme (though clinical effectiveness
was not proven in one component trial, CHARM Preserved).
There was, however, heterogeneity between the component
trials in the programme. Although candesartan treatment
was associated with either a small reduction or increase in
the net overall cost of care in CHARM-Alternative and
CHARM-Added, depending on the analysis, in CHARM-
Preserved (in which candesartan treatment did not reduce
the primary endpoint signiﬁcantly) there was a consistent
and modest increase in the net cost of care. There appear
to be two reasons for this. Though the proportional
reduction in the rate and number of admissions for worsen-
ing HF was similar in all three CHARM trials, the absolute
number of admissions prevented was smaller, relative to
the number of patients treated, in CHARM-Preserved (i.e.
the rate of admission for worsening HF was lower in CHARM-
Preserved, Figure 2). Consequently, the cost-offset was less
in CHARM-Preserved than in the other two trials. A second
explanation was the increased number of ‘other’ cardiovas-
cular admissions in the candesartan group in CHARM-
Preserved (a reduction, rather than excess, of these
admissions was observed in the other CHARM trials). A
similar increase was observed with cardiovascular pro-
cedures in CHARM-Preserved. No clear pattern could be dis-
cerned in either excess suggesting that both increases may
have been a chance ﬁnding. That the overall net cost of
treatment in CHARM-Added was comparable with that
obtained in CHARM-Alternative is notable, given that
candesartan was added to full conventional treatment,
including an ACE-inhibitor, in the former trial. It is also
notable that the essentially cost-neutral outcome of these
analyses of CHARM was obtained despite adding the cost of
extra clinic visits and biochemical tests to reﬂect the
extra costs related to initiating, up-titrating the dose, and
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Our ﬁndings on the cost–consequences of using
candesartan are broadly in keeping with economic analyses
of other effective treatments for HF though difﬁcult to
compare directly.22,37–39 No other placebo-controlled study
included such a broad spectrum of patients, had within-trial
data for such a long period of follow-up (with the exception
of the ACE-inhibitor enalapril in the treatment arm of the
studies of LV dysfunction in the case of the latter36), or
added the test drug to such extensive background treatment.
Nevertheless, a consistent message from these prior econ-
omic analyses and ours is that reduction in hospital admission
offsets the cost of treatment. Remarkably, the cost-offset has
been sufﬁcient with all treatments examined, to date, to be
cost-saving or more or less cost-neutral. This is despite each
new drug being used as an additional treatment and against a
trend of falling lengths of hospital stay.
These economic results, coupled with the clinical ﬁndings
of the CHARM programme, have clear implications for the
management of patients with HF.17–21,40 Not only does
candesartan improve all important clinical outcomes in HF
but also offers these beneﬁts at little or no additional cost
to the health care system; indeed, its use in patients with
HF and reduced LV systolic function may lead to an actual
reduction in the direct costs of health care. This is an
important ﬁnding for health-care providers and society
more generally, because there is no trade-off between the
interest of the individual patient (and it seems unlikely
that many patients would prefer the outcomes expected
without candesartan) and the greater population served by
the health-care system.
As with any analysis of this type there were limitations. By
using the full unit cost of candesartan, our analyses have
reduced the cost-effectiveness of this treatment for
countries such as France where the patient or a private
insurer pays 35% of the cost of treatment. We did not take
account of indirect costs, such as loss of productivity due
to inability to work; this, however, was unlikely to be a
major problem because 54% of patients were beyond retire-
ment age at the time of randomization. Pension payments in
those who survived were not taken account of and there
were more survivors in the candesartan group. We did not
consider the cost related to death out of hospital, though
there were more of these in the placebo group, this was a
conservative approach. We did not incorporate quality of
life information. We had less detailed and complete infor-
mation on non-cardiovascular procedures and drugs.
However, the main driver of costs is hospital admission and
we did have information on these and tried to account for
lack of information on the former in our sensitivity analyses.
As with all economic analyses based on clinical trials of
limited duration, there is concern that costs may only be
postponed and that there may be ‘catch-up’ over the
whole life-time of a patient. We believe that this is unlikely
given the relatively long-duration of follow-up of CHARM
(37.7 months) compared with the average life-expectancy
of patients with HF. Another question about economic ana-
lyses is how far they can be generalized, geographically.
We chose to focus on France, Germany, and the UK
because robust national costs are available from govern-
ment sources in these countries. We found very similar net
consequences in each country and this ﬁnding and prior ana-
lyses suggest that broadly similar conclusions can be antici-
pated in other countries, given that in all countries, the cost
of HF is mainly driven by hospital admissions. Clearly,
however, a greater unit cost of candesartan, shorter (or
otherwise less expensive) hospital stays or, especially,
both, would make the cost outcome less favourable.
Finally, we carried out a cost–consequence analysis of
CHARM-Preserved even though the pre-speciﬁed primary
outcome was not reduced signiﬁcantly.
In summary, when added to currently recommended
treatment, candesartan improves functional limitation due
to symptoms,40 reduces hospital admissions for worsening
HF17–20 and increases survival in patients with HF and a
low LVEF20,21 and does this at little or no extra direct cost
to the health-care system. candesartan is, therefore, a clini-
cally and economically attractive adjunctive treatment for
those patients, representing a ‘win-win’ scenario for both
the individual patient and health-care providers.
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